Skip to main content

17 Education & Technology Group Inc. Announces First Quarter 2025 Unaudited Financial Results

BEIJING, June 11, 2025 (GLOBE NEWSWIRE) — 17 Education & Technology Group Inc. (NASDAQ: YQ) (“17EdTech” or the “Company”), a leading education technology company in China, today announced its unaudited financial results for the first quarter of 2025. First Quarter 2025 Highlights1Net revenues were RMB21.7 million (US$3.0 million), compared with net revenues of RMB25.5 million in the first quarter of 2024. Gross margin was 36.2%, compared with 38.4% in the first quarter of 2024. Net loss was RMB30.9 million (US$4.3 million), compared with net loss of RMB56.1 million in the first quarter of 2024. Net loss as a percentage of net revenues was negative 142.8% in the first quarter of 2025, compared with negative 219.9% in the first quarter of 2024. Adjusted net loss2 (non-GAAP), which excluded share-based compensation expenses...

Continue reading

Vocus and Telesat announce multi-year Telesat Lightspeed terrestrial infrastructure and services contract

MELBOURNE, Australia and OTTAWA, Canada, June 10, 2025 (GLOBE NEWSWIRE) — Vocus, Australia’s specialist digital infrastructure provider, and Telesat (Nasdaq and TSX: TSAT), one of the world’s most innovative satellite operators, today announced that Vocus will build Australia’s first Telesat Lightspeed Low Earth Orbit (LEO) Landing Station. Vocus will construct and operate the new Landing Station in New South Wales, Australia and provide fibre connectivity to Telesat’s point of presence (PoP), connecting Telesat’s advanced LEO satellite constellation, called Telesat Lightspeed, to terrestrial networks, providing secure, low-latency satellite services across the region. “As a leading provider of Landing Stations and fibre network solutions, Vocus is an ideal partner to deliver the resilient, scalable...

Continue reading

Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial

SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced it will release topline data from the norovirus Phase I trial before the market open on Wednesday, June 11, 2025. The Vaxart senior management team will host a live conference call on the same date beginning at 8:30 a.m. Eastern Time to review the data and provide a trial update. The conference call can be accessed using the following information: Webcast: Click hereDate: Wednesday, June 11, 2025 – 8:30 a.m. ETDomestic: (877) 407-0832International: (201) 689-8433Conference ID: 13754315 Investors may submit written questions in advance of the conference call to ir@vaxart.com. A replay of the...

Continue reading

Canoe Financial announces changes to its mutual fund lineup

CALGARY, Alberta, June 10, 2025 (GLOBE NEWSWIRE) — Canoe Financial LP (“Canoe Financial”) today announced changes to two of its investment funds. Fund name changes Effective June 20 2025, the following name changes will take effect:Canoe Defensive Global Balanced Fund will be renamed Canoe Fundamental Global Balanced Fund Canoe Canadian Small Mid Cap Portfolio Class will be renamed Canoe Fundamental Small Mid Cap Portfolio ClassThese changes reflect Canoe Financial’s continued focus on clarity, precision and alignment between fund names and investment strategies. Canoe Fundamental Global Balanced FundThe new name reflects the fund’s change in investment strategy to focus on fundamental, bottom-up security selection, in alignment with Canoe Financial’s investment process. This change also removes the risk management overlay...

Continue reading

IREN announces proposed convertible notes offering

SYDNEY, June 10, 2025 (GLOBE NEWSWIRE) — IREN Limited (NASDAQ: IREN) (ACN 629 842 799) (“IREN”) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). IREN also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50 million principal amount of notes. Description of notes The notes will be senior, unsecured obligations of IREN, will accrue interest payable semi-annually in arrears and will mature...

Continue reading

Micropolis Holding Company Filed Annual Report on Form 20-F for the Year Ended December 31, 2024

DUBAI, United Arab Emirates, June 10, 2025 (GLOBE NEWSWIRE) — Micropolis Holding Company (“Micropolis” or the “Company”) (NYSE American: MCRP), a pioneer in unmanned ground vehicles and AI-driven security solutions, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission (the “SEC”) on May 8, 2025. The annual report on Form 20-F, which contains Micropolis’ audited annual financial statements for the fiscal year ended December 31, 2024, can be accessed on the SEC’s website at http://www.sec.gov, as well as via the Company’s investor relations website at https://investors.micropolis.ai/filings. The Company will deliver a hard copy of its 2024 annual report on Form 20-F, including its complete audited financial statements, free of...

Continue reading

Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors

WALTHAM, Mass., June 10, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Akintunde (Tunde) Bello, Ph.D., to the company’s board of directors. “Tunde is an accomplished leader with a strong track record of successfully developing novel therapies across a broad range of therapeutic areas, including several important cancer immunotherapies for anti-CTLA-4, PD-1 and T-cell engager through all stages of development, and I am thrilled to welcome him to the board,” said Paul Clancy, chair of the board of directors of Xilio Therapeutics. “With over 25 years of experience in oncology research and development, focused on translational medicine and clinical...

Continue reading

Globalink Investment Inc. Announces Charter and Trust Agreement Amendments

New York, NY, June 10, 2025 (GLOBE NEWSWIRE) — Globalink Investment Inc. (OTC Pink: GLLI, GLLIW, GLLIR, GLLIU) (“Globalink” or the “Company”), a special purpose acquisition company, announced today that its stockholders approved amendments to its charter and trust agreement to extend the deadline to complete its initial business combination and change the structure and cost of such extensions. Under the amended charter, Globalink may extend the deadline to complete its initial business combination by up to six (6) monthly extensions, from June 9, 2025 to December 9, 2025 by depositing $0.15 per public share into its trust account (the “Trust Account”) with Continental Stock Transfer and Trust Company (“Continental”). Globalink’s stockholders, at a special meeting of its stockholders held on June 4, 2025, approved an amendment to...

Continue reading

Purpose Unlimited Announces Completion of Steadyhand Acquisition

TORONTO, June 10, 2025 (GLOBE NEWSWIRE) — Purpose Unlimited Inc. (“Purpose” or “Purpose Unlimited”), a rapidly growing Canadian financial services firm, announced today that it has completed its acquisition of Steadyhand Investment Management Ltd. and Steadyhand Investment Funds Inc. (collectively, “Steadyhand”), an independent Vancouver-based wealth management firm with approximately $1.3 billion in assets serving Canadian investors. “We’re excited to begin this new chapter with Steadyhand,” said Som Seif, founder and CEO of Purpose Unlimited. “Steadyhand has earned a remarkable reputation for putting investors first, with a disciplined, outcome-focused approach and exceptional client care. While Purpose brings a broader platform and an innovative mindset, we’ve long respected how Steadyhand serves its clients—and we’re...

Continue reading

BrightSpring Announces Secondary Offering of Common Stock

LOUISVILLE, Ky., June 10, 2025 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (NASDAQ: BTSG) (“BrightSpring” or the “Company”), a leading provider of home and community-based health services for complex populations, today announced that certain of its stockholders (the “Selling Stockholders”), including affiliates of Kohlberg Kravis Roberts & Co. L.P. (the “KKR Selling Stockholder”) and certain members of management, intend to offer for sale in an underwritten secondary offering an aggregate 14,000,000 shares of common stock of BrightSpring pursuant to a shelf registration statement filed by BrightSpring with the U.S. Securities and Exchange Commission (the “SEC”). The KKR Selling Stockholder expects to grant the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of BrightSpring’s common stock....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.